What is she best known for?
The fields of study she is best known for:
- Gene
- Cancer
- Immune system
Andrea Anichini spends much of her time researching Immunology, Cancer research, Antigen, Cytotoxic T cell and Melanoma.
Andrea Anichini focuses mostly in the field of Cancer research, narrowing it down to matters related to Mutation and, in some cases, Carcinogenesis, Oncogene and Receptor.
In Antigen, Andrea Anichini works on issues like Immunotherapy, which are connected to Immunogenicity, Monoclonal, Phases of clinical research and Cisplatin.
Her Cytotoxic T cell research is multidisciplinary, incorporating elements of Melanocyte differentiation and CD3.
The various areas that Andrea Anichini examines in her Melanoma study include Monoclonal antibody and Pathology.
Her research in CTL* focuses on subjects like Molecular biology, which are connected to HLA-A2 Antigen and Clone.
Her most cited work include:
- Role of Macrophage Targeting in the Antitumor Activity of Trabectedin (482 citations)
- Interleukin-12: biological properties and clinical application. (442 citations)
- Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? (376 citations)
What are the main themes of her work throughout her whole career to date?
Her primary scientific interests are in Cancer research, Immunology, Melanoma, Cytotoxic T cell and Antigen.
Her Cancer research research is multidisciplinary, incorporating perspectives in Apoptosis, Programmed cell death, Receptor tyrosine kinase and Oncogene.
T cell, CD8, Immune system, T-cell receptor and Immunotherapy are among the areas of Immunology where the researcher is concentrating her efforts.
Her study in Immune system is interdisciplinary in nature, drawing from both Immunohistochemistry, Cancer and Internal medicine.
Her studies examine the connections between Melanoma and genetics, as well as such issues in Integrin, with regards to Cell biology.
The concepts of her Cytotoxic T cell study are interwoven with issues in Molecular biology, T lymphocyte and CD3.
She most often published in these fields:
- Cancer research (40.43%)
- Immunology (39.36%)
- Melanoma (36.70%)
What were the highlights of her more recent work (between 2017-2021)?
- Cancer research (40.43%)
- Pembrolizumab (4.26%)
- Urology (4.26%)
In recent papers she was focusing on the following fields of study:
Her scientific interests lie mostly in Cancer research, Pembrolizumab, Urology, Internal medicine and Immunotherapy.
Andrea Anichini is studying Melanoma, which is a component of Cancer research.
She works mostly in the field of Pembrolizumab, limiting it down to topics relating to Cystectomy and, in certain cases, Phases of clinical research and Cisplatin, as a part of the same area of interest.
Her Internal medicine research is multidisciplinary, relying on both Gastroenterology and Oncology.
Her Immunotherapy study which covers Tumor microenvironment that intersects with Gene regulatory network, Computational biology, Gene and Gene signature.
Her Antigen research includes elements of Cytotoxic T cell and Monoclonal antibody.
Between 2017 and 2021, her most popular works were:
- Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study (208 citations)
- Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade (157 citations)
- The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy (23 citations)
In her most recent research, the most cited papers focused on:
- Gene
- Cancer
- Immune system
Her primary areas of study are Cancer research, Melanoma, Immunotherapy, Immunohistochemistry and Immune system.
Andrea Anichini combines subjects such as Semaphorin, Cell migration, Lung cancer, Antibody and Gene silencing with her study of Cancer research.
Her Antibody research incorporates elements of Cancer cell, Cytotoxic T cell, CD3 and Antigen.
Her Melanoma study combines topics from a wide range of disciplines, such as Apoptosis, Transcription factor, Metastasis and Blot.
Her studies deal with areas such as Cystectomy, Carcinoma and Urology as well as Immunotherapy.
Her Immune system research includes themes of Cancer therapy, Disease and Intensive care medicine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
